Third Harmonic Bio, Inc.
THRDDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001923840
Third Harmonic Bio, Inc. was delisted in 2025; its insiders filed their last Form 4 on Aug 14, 2025; 107 institutions reported holding it in 13F filings for Q2 2025, worth $210.3M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Third Harmonic Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Third Harmonic Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Iwicki Mark T | Director | 0 | Aug 14, 2025 | 0 |
| Soloway Thomas P | Director | – | Aug 14, 2025 | 0 |
| Bonita David P | Director | 0 | Aug 14, 2025 | 0 |
| Holles Natalie C. | CEO | 0 | Aug 14, 2025 | 0 |
| Gladstone Michael | Director, 10% Owner | – | Aug 14, 2025 | 0 |
| Seidel Hans Martin | Director | 0 | Aug 14, 2025 | 0 |
| Murphy Christopher M. | Chief Financial & Bus. Officer | – | Aug 14, 2025 | 0 |
| Conner Edward R. | Chief Medical Officer | 0 | Jan 17, 2025 | 0 |
| Dinsmore Christopher | Chief Scientific Officer | – | Jan 17, 2025 | 0 |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER | 0 | Jan 17, 2025 | 0 |
| Dittman Jennifer | Chief Operating Officer | 0 | Jan 17, 2025 | 0 |
| Dean Dennis | Chief Nonclinical Dev. Officer | – | Jan 17, 2025 | 0 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 9,798,075 | Nov 5, 2024 | 0 |
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| BVF Partners L P | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| BVF Inc | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| Lampert Mark N | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| BVF GP Holdings LLC | Other: See Explanation of Responses | 176,692 | Oct 31, 2024 | 0 |
| McDonough Geoff | Director | – | Mar 28, 2024 | 0 |
| Perez Robert J | Director | – | Mar 8, 2023 | 0 |
| Ho Robert | Chief Financial Officer | – | Mar 8, 2023 | 0 |
| Ray Adrian S. | Chief Scientific Officer | – | Mar 8, 2023 | 0 |
| Lin Shao-Lee | Director | – | Oct 27, 2022 | 0 |
| OrbiMed Advisors LLC | Director, 10% Owner | 5,779,071Indirect | Sep 21, 2022 | 0 |
| OrbiMed Capital GP VII LLC | Director, 10% Owner | 5,779,071Indirect | Sep 21, 2022 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 594,096 | Sep 19, 2022 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 594,096 | Sep 19, 2022 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 594,096 | Sep 19, 2022 | 0 |
| Atlas Venture Associates XI, LLC | 10% Owner | 594,096 | Sep 19, 2022 | 0 |
| Atlas Venture Associates XI, L.P. | 10% Owner | 594,096 | Sep 19, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 (view filing) | Nov 8 | 4 days | Conner Edward R.Chief Medical Officer | SSale | −2.12K | $15.00 | −$31.8K | −100.0%0 after | 10b5-1 |
| Oct 31, 2024 (view filing)5:53 PM ET | Oct 29 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | SSale | −1.00M | $14.30 | −$14.3M | −85.0%176.7K after | 3 lots |
| Oct 30, 2024 (view filing) | Oct 28 | 2 days | Conner Edward R.Chief Medical Officer | SSale | −2.67K | $15.00 | −$40.1K | −100.0%0 after | 10b5-1 |
| Sep 20, 2024 (view filing) | Sep 19 | 1 day | Conner Edward R.Chief Medical Officer | SSale | −4.79K | $15.00 | −$71.8K | −100.0%0 after | 10b5-1 |
| Sep 20, 2024 (view filing) | Sep 18-19 | 2 days | Person JulieCHIEF ADMINISTRATIVE OFFICER | SSale | −10.0K | $14.28 | −$142.8K | −100.0%0 after | 2 lots10b5-1 |
| Jun 28, 2024 (view filing) | Jun 26 | 2 days | Person JulieCHIEF ADMINISTRATIVE OFFICER | SSale | −10.0K | $12.46 | −$124.6K | −100.0%0 after | 10b5-1 |
| Jun 10, 2024 (view filing) | Jun 7 | 3 days | Dittman JenniferChief Development Oper Officer | SSale | −494 | $14.17 | −$7.00K | −100.0%0 after | 10b5-1 |
| May 22, 2024 (view filing) | May 20 | 2 days | Dittman JenniferChief Development Oper Officer | SSale | −1.04K | $14.00 | −$14.6K | −100.0%0 after | 10b5-1 |
| May 20, 2024 (view filing) | May 16 | 4 days | Dittman JenniferChief Development Oper Officer | SSale | −23.6K | $14.04 | −$331.0K | −100.0%0 after | 10b5-1 |
| May 10, 2024 (view filing) | May 9 | 1 day | Holles Natalie C.CEO | SSale | −20.2K | $12.18 | −$246.3K | −1.6%1.22M after | 10b5-1 |
| Apr 15, 2024 (view filing) | Apr 11 | 4 days | Holles Natalie C.CEO | SSale | −13.6K | $12.19 | −$165.3K | −1.1%1.22M after | 10b5-1 |
| Apr 8, 2024 (view filing) | Apr 4 | 4 days | Person JulieCHIEF ADMINISTRATIVE OFFICER | SSale | −1.11K | $10.00 | −$11.1K | −100.0%0 after | 10b5-1 |
| Dec 7, 2023 (view filing) | Dec 5 | 2 days | Person JulieChief Administrative Officer | SSale | −12.9K | $10.30 | −$132.5K | −100.0%0 after | 10b5-1 |
| Dec 7, 2023 (view filing) | Dec 5 | 2 days | Conner Edward R.Chief Medical Officer | SSale | −4.79K | $10.03 | −$48.0K | −100.0%0 after | 10b5-1 |
| Dec 22, 2022 (view filing)6:49 PM ET | Dec 20 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +214.1K | $4.11 | +$879.5K | +785.7%241.3K after | 3 lots |
| Sep 21, 2022 (view filing)6:00 PM ET | Sep 19 | 2 days | OrbiMed Advisors LLC and 1 otherDirector, 10% Owner | PPurchase | +300.0K | $17.00 | +$5.10M | +5.5%5.78M after | Duplicate filing |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Bonita David PDirector, 10% Owner | PPurchase | +300.0K | $17.00 | +$5.10M | +5.5%5.78M after | |
| Sep 19, 2022 (view filing)4:51 PM ET | Sep 19 | Same day | Atlas Venture Fund XI, L.P. and 5 others10% Owner | PPurchase | +300.0K | $17.00 | +$5.10M | +3.0%10.3M after |